Dasatinib and FLAG-IDA Is an Effective Therapy for Initial Myeloid Blast Crisis but Involves a High Risk of Opportunistic Infections.


Journal

Case reports in hematology
ISSN: 2090-6560
Titre abrégé: Case Rep Hematol
Pays: United States
ID NLM: 101576456

Informations de publication

Date de publication:
2020
Historique:
received: 29 05 2020
revised: 15 10 2020
accepted: 24 10 2020
entrez: 23 11 2020
pubmed: 24 11 2020
medline: 24 11 2020
Statut: epublish

Résumé

Blast crisis (BC) continues to be the major challenge in the treatment of chronic myeloid leukemia. Best results have been observed in a few patients who were successfully transplanted after returning to chronic phase. Recent studies focus on the combination of chemotherapy with imatinib, but results remain unsatisfactory. Since dasatinib induces deeper and faster responses, a reasonable strategy might be to combine it with chemotherapy, taking into account the alterations in T-cell response induced by dasatinib. However, there are no published studies or case reports supporting the use of dasatinib as first line treatment for initial myeloid BC, and very little is known about infectious complications associated with this drug. Based on this, we present the case of a patient diagnosed with an initial nonlymphoid phenotype BC, who achieved molecular response (MR

Identifiants

pubmed: 33224541
doi: 10.1155/2020/8867461
pmc: PMC7673920
doi:

Types de publication

Case Reports

Langues

eng

Pagination

8867461

Informations de copyright

Copyright © 2020 Jorge Labrador et al.

Déclaration de conflit d'intérêts

The authors declare that they have no conflicts of interest.

Références

Cancer. 1999 Dec 15;86(12):2632-41
pubmed: 10594858
Cancer. 2007 Apr 15;109(8):1543-9
pubmed: 17340589
Leuk Lymphoma. 2007 Dec;48(12):2308-9
pubmed: 18067004
Eur J Clin Invest. 2009 Dec;39(12):1098-109
pubmed: 19744184
Blood. 2012 Jul 26;120(4):737-47
pubmed: 22653972
Blood. 2008 Feb 1;111(3):1366-77
pubmed: 17962511
Br J Haematol. 2009 Jan;144(2):195-205
pubmed: 19016717
Haematologica. 2008 Dec;93(12):1792-6
pubmed: 18838477
N Engl J Med. 2001 Apr 5;344(14):1038-42
pubmed: 11287973
Haematologica. 2012 Mar;97(3):473-4
pubmed: 22133777
Blood. 2002 May 15;99(10):3530-9
pubmed: 11986204
Blood. 2002 May 15;99(10):3547-53
pubmed: 11986206
Leuk Lymphoma. 2007 Dec;48(12):2461-4
pubmed: 18067026
Clin Cancer Res. 2008 Apr 15;14(8):2484-91
pubmed: 18413841
Cancer. 2010 Aug 15;116(16):3852-61
pubmed: 20564086
Expert Opin Investig Drugs. 2007 May;16(5):679-87
pubmed: 17461740

Auteurs

Jorge Labrador (J)

Department of Hematology, University Hospital of Burgos, Burgos, Spain.

Gerardo J Hermida (GJ)

Department of Hematology, University Hospital of Burgos, Burgos, Spain.

Rodolfo Alvarez (R)

Department of Hematology, University Hospital of Burgos, Burgos, Spain.

Victor Anso (V)

Department of Hematology, University Hospital of Burgos, Burgos, Spain.

Pilar de Vicente (P)

Department of Hematology, University Hospital of Burgos, Burgos, Spain.

Mercedes Goñi (M)

Department of Hematology, University Hospital of Burgos, Burgos, Spain.

Tomas Jose Gonzalez-Lopez (TJ)

Department of Hematology, University Hospital of Burgos, Burgos, Spain.

Classifications MeSH